Mass Cytometry in Vaccine Development: Utility and Considerations


Integrating mass cytometry into candidate vaccine development

In this presentation, Patrick Reeves, PhD, discusses how mass cytometry can benefit vaccine research programs to overcome hurdles, deliver valuable insights and inform the evaluation of candidate vaccines.

Reeves describes some of the advantages of using mass cytometry in vaccine studies including:

  • Obtaining high-data density per sample volume when limited samples are available
  • Fixation steps embedded in workflow contribute to biosafety of materials
  • Site-to-site data consistency
  • Applications such as phospho-flow, tetramer panels, and whole blood analysis with mass cytometry enable deeper investigation

Results and lessons from the development of a novel vaccine for Coxiella burnetii and other examples illustrate key benefits, challenges and considerations for integrating mass cytometry into vaccine research programs.

Learn more about the use of mass cytometry in vaccine research

About the presenter:

Patrick Reeves, PhD
Instructor in Medicine, Harvard Medical School
Team Leader, Vaccine and Immunotherapy Center,
Massachusetts General Hospital

This webinar first aired on July 7, 2020, at the Fluidigm Infectious Disease and Oncology Virtual Summit.


Contact us to learn more about mass cytometry.

For Research Use Only. Not for use in diagnostic procedures.